The National Psoriasis Foundation (NPF) today announced a significant advancement in patient-centered care following the adoption of a position statement from the NPF Medical Board and the International Psoriasis Council (IPC).
Based on a comprehensive review of emerging scientific evidence, the NPF Medical Board determined that tuberculosis testing is no longer necessary for certain psoriatic disease treatments due to their mechanism of action and safety profile. This position was subsequently brought to the U.S. Food and Drug Administration (FDA) in partnership with an NPF pharmaceutical partner and Corporate Member developing a new oral treatment.
Following review, the FDA determined that patients prescribed the therapy would not be required to undergo TB testing. This removes a longstanding barrier that can delay treatment initiation, add costs, and increase the burden for people living with psoriatic disease.
“This decision reflects the real-world impact of the Medical Board’s work,” said Guy Eakin, Ph.D., Chief Scientific and Medical Officer of NPF. “When small changes like this add up, they make a real difference in people’s daily lives and move us closer to our vision of a world without psoriatic disease and its burdens.”
The outcome highlights NPF’s role as a trusted, science-driven advocate at the intersection of patient needs, clinical expertise, and regulatory decision-making. Through collaboration with regulators and industry partners, NPF continues to work toward improving access to care and advancing patient-centered treatment pathways.
About the National Psoriasis Foundation
The National Psoriasis Foundation is the leading nonprofit representing individuals with psoriasis and psoriatic arthritis. The mission of NPF is to drive efforts to cure psoriatic disease and improve the lives of more than 8 million individuals in the United States affected by this chronic immune-mediated disease. Learn more at psoriasis.org.